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Abstract
Background. Fabry disease (FD) is a genetic disorder
characterized by accumulation of trihexosylceramide
in lysosomes of various tissues leading to multiorgan
manifestations, including progressive renal disease.
Previous screening studies have shown that a non-
neglectable proportion of haemodialysis(HD) patients
have unsuspected FD. An extensive FD screening
study, the largest to date, has been conducted in HD
patients in Czech Republic. We aimed to uncover
previously undiagnosed FD patients, to enable them
to benefit from cause-specific therapeutic inter-
vention with enzyme replacement therapy (ERT).
Methods. Large-scale screening was executed using
a convenient automated enzymatic (a-galactosidose A,
a-Gal A) dried blood spot on filter paper fluorescence
method.
Results. In total, 3370 (45.1% males, 54.9% females)
out of 4058 HD patients (83%) in Czech Republic
participated in this blood spot screening (BSS) study.
Abnormal low fluorescence readings were obtained
in 117 patients (3.5%). Subsequent determination of
plasma a-Gal A activity identified four males and
three females with deficient plasma enzyme activity.
Determination of a-Gal A activity in peripheral blood
leucocytes and confirmatory molecular analysis
resulted in four newly diagnosed Fabry males
and one female. Subsequent family screening identified
10 family members with genotypically proven FD.
Based on these screening results, ERT could be
offered to five male FD patients.
Conclusions. BSS represents a promising screening tool
that has proven to be convenient and effective in
uncovering unrecognized FD patients among the
chronic HD population in Czech Republic.
Keywords: blood spot screening; end-stage renal
disease; enzyme replacement therapy; Fabry disease;
a-galactosidase A; haemodialysis
Introduction
Fabry disease (FD) is a rare X-linked genetic lysosomal
storage disorder resulting from a defect in the gene
encoding lysosomal a-galactosidase A (a-Gal A, EC
3.2.1.22). Estimates of the frequency of FD range
between 1: 40000 and 240000 male individuals [1–3].
The calculated prevalence of FD in Czech population is
1 in 110000 male live births but the frequency is
obviously higher in at risk subpopulations, such as
patients requiring chronic haemodialysis (HD).
In FD, the deficiency of a-Gal A results in
progressive lysosomal accumulation of neutral
glycosphingolipids with terminal a-galactose moieties,
predominantly globotriaosylceramide (Gb3).
Accumulation occurs in many cell types, particularly
in vascular endothelial cells, renal epithelial cells,
pericytes, vascular smooth muscle cells, cardio-
myocytes and neurons.
Genetically, the disease is described as an X-linked
recessive disorder. Affected hemizygote males have
absent or very low levels of lysosomal a-Gal A
and the majority of these patients will present with
the so-called ‘classic’ phenotype with onset of symp-
toms (angiokeratomas, hypohidrosis, acroparesthesias)
during childhood [1]. With advancing age, vascular
involvement may lead to end-stage renal
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and stroke. Death usually occurs in the third to fifth
decade of life. Less frequent phenotypes include the
renal and cardiac variants. Patients with the renal
variant usually have low plasma a-Gal A activity and
a milder phenotype, but they may progress to ESRD
necessitating HD. In addition, a cardiac variant is seen
in males. X-chromosome inactivation in an early stage
of embryonic development may (partly) account for
the fact that females may be as severely affected
as males with FD [4]. However, in women evidence
of organ system involvement may be present without
overt clinical symptoms.
The gene that encodes a-Gal A comprises seven
exons and has been isolated, sequenced and localized to
the chromosomal region Xq22.1 [5,6]. To date, over 245
mutations of the gene have been identified including
non-sense (null) and missense mutations, and splice
junction, deletion and insertion errors [7]. Null muta-
tions lead to the complete abolition of the gene tran-
scription into RNA or its translation into functional
protein. Active site mutations can reduce enzymatic
activity by perturbing the active site while the overall
structure of the enzyme remains unaffected. Folding
mutations may destabilize the a-Gal A protein struc-
ture, e.g. by disrupting its hydrophobic core. Since most
mutations are private and occur in single FD families,
attempts to ascertain strict genotype/phenotype corre-
lations generally have been unsuccessful.
The recent introduction of cause-specific enzyme
replacement therapy (ERT) with recombinant a-Gal A
has renewed the interest in FD, and has initiated
several screening studies that aimed to identify ESRD
patients with unsuspected FD. The diagnosis of FD in
hemizygotes is primarily based on demonstration
of deficient a-Gal A activity, preferably in leucocytes.
In heterozygotes, the diagnosis should be established
by mutation testing as enzyme activity may be found
within the normal range.
Screening studies that used plasma samples were
successful in identifying new FD patients [8,9].
However, for larger-scale screening in high-risk
populations management of the logistic burden
would be challenging and expensive. The encouraging
results, of the first studies that used the FD blood spot
screening (BSS) test [10–12], were the stimulus for
undertaking a BSS study in Czech Republic that aimed
to identify undiagnosed FD patients among
the chronic HD patient population. We present the
results of this nationwide FD screening study—to date,
the largest BSS study that has been conducted.
Furthermore, we evaluate the value of the BSS filter
paper test as a diagnostic tool in FD.
Subjects and methods
Study design and protocol of BSS study
The nationwide screening for FD among chronic HD patients
was performed in all 14 regions of Czech Republic in 2002.
The study was coordinated at the Department of Nephrology
and the Institute of Inherited Metabolic Disorders of the
1stMedical Faculty of the Charles University andthe General
Faculty Hospital in Prague, Czech Republic. Approval
was obtained from the Ethical Committee of the General
Faculty Hospital. All 88 HD centres in Czech Republic were
invitedtoparticipateinthisBSSstudy,andweresuppliedwith
patient information materials, as well as with filter papers to
execute the screening test. The local study coordinators at
thevariousHDcentrescollaboratedontheimplementation of
the BSS study protocol at the investigational sites. HD
patients were informed about the BSS study specifics, and
thosewhoagreedonparticipationprovidedinformedconsent.
Genotyping in confirmed a-Gal A deficient patients was
performed with specific written informed consent. The BSS
study was designed (i) to test patients with ESRD on
chronic HD treatment by means of dried blood spot testing,
(ii) to confirm or exclude positive BSS results by measuring
a-Gal A activity in blood plasma, (iii) to confirm the positive
plasma results by determining a-Gal A activity in periph-
eral blood leucocytes and additionally by analysis of urinary
Gb3, if urine samples were available (iv) to confirm the
diagnosis of FD by molecular analysis of the GLA gene.
Dried blood spot test
Whole blood samples were taken from patients undergoing
HD and a few drops were transferred to the BSS filter papers.
These were collected, dried at room temperature, stored at
2–88C and sent for analysis to the Laboratory of the Regina
Margherita Children’s Hospital in Torino, Italy. The dried
blood spots were analysed using a fluorescence-based high
throughput microplate method. The BSS test result was
defined as positive if the a-Gal A activity was found below
the threshold of 1.5nmol/h/ml, which represents approxi-
mately 35% of the a-Gal A activity in healthy controls.
The methodology was based on the results of two published
pilot studies [10,11].
a-Gal A activity in blood plasma and peripheral
blood leukocytes
Plasma was separated from ethylendiaminetetraacetic acid
(EDTA) blood (2–3ml) by centrifugation at 2000g.
Leucocytes were isolated from 5–7ml EDTA blood using
differential dextran sedimentation, erythrocyte lysis and
centrifugation at 300g [13]. Enzyme activities of a-Gal A
and control enzymes (b-galactosidase and b-hexosaminidase)
were assayed in plasma samples or in total cell homogenates
with artificial 4-methylumbelliferyl (4-MU) substrates [14].
Fluorescence of released 4-MU was measured at excitation
365 and emission 448nm on the luminescence spectrometer
(Perkin Elmer LS50B, Wellesley, USA). Values in leucocytes
were expressed as nanomoles (nmol) of substrate degraded
per hour per mg of the cell protein; values in plasma as nmol
per hour per ml of plasma, at 378C.
Analysis of glycolipids in urine
Gb3 in urinary sediments was extracted with chloroform-
methanol (2:1, v/v) and analysed on HPTLC plates (Silica
gel Merck, Germany) [15].
180 M. Merta et al.Mutation testing
Genomic DNA and total RNA were extracted from
peripheral blood leucocytes or from cultured skin fibroblasts.
Genomic DNA was isolated with QiaAmp columns
(Qiagen). Total RNA was prepared from white blood cells
or cultured skin fibroblasts [16]. Messenger RNA was
reverse-transcribed using SuperScriptII reverse transcriptase
(Gibco BRL) and oligo(dT)18 according to the protocol
supplied by the manufacturer. The sequencing procedure
and primer sequences have been described in detail elsewhere
[17,18]. In all relatives of identified patients, sequencing
was performed both on cDNA and genomic DNA. This
approach increased the probability of identifying potential
splicing variants caused by mutation and minimize the risk
of sequencing only one transcribed allele in female samples
(e.g. due to the unbalanced expression of the alleles in tissue).
We also designed the PCR/RFLP or ARMS (Little S)
method for further confirmation of the identified mutation,
as well as for rapid screening of probands’ family members.
Statistical analyses
Data are shown as mean SD.
Results
Study population
In total, 3370 out of 4058 patients (83%) from
the overall HD population in Czech Republic partici-
pated in this BSS study (Table 1). There were 1521
(45.1%) males and 1849 (54.9%) females. The patients
were recruited at 76 out of the 88 (86.3%) Czech HD
centres. One male patient who already had been
diagnosed with FD underwent BSS testing, but was
not additionally tested for enzyme activity or geno-
typing under this study Protocol.
BSS test and a-Gal A activity in plasma and
peripheral blood leucocytes
The BSS test result was positive (abnormal low
fluorescence reading) in 117/3370 enrolled patients
(3.5%) of whom 58 (49.6%) were males and 59
(50.4%) females (Table 1). Results of plasma and
leucocyte a-Gal A tests are specified in Table 2 per
patient and as ranges and means for healthy controls,
classic FD controls, cardiac variant FD controls
and for a control group of FD heterozygotes. In 7
(four males, three females; Table 1) out of the 117
BSS positive individuals, the plasma a-Gal A activity
was below the limit set at 3nmol/h/ml (because
females were included in the study, this limit was set
higher than the limit normally used in males)
(Figure 1). Verification of enzyme deficiency in
peripheral blood leucocytes in these seven patients
revealed leucocyte a-Gal A deficiency in three males
(patients 1, 3 and 4) and decreased enzyme activity in
male patient 2 and decreased (patient 5) or borderline
activity (patient 6 and 7) in three females. The very
unusual high residual activity in leucocytes obser-
ved in male patient 2 (higher than the activity in
patient 1 with a mild cardiac variant, Table 2) will be
Table 1. Results of BSS testing in the HD patient population in
Czech Republic
HD population tested with BSS test Men
a Women
b Total
1521 1849 3370
BSS test positive 58 59 117
a-Gal A activity (plasma
and leucocytes) abnormal
43 7
Identification of GLA mutation 4 1 5
aDeficient/decreased.
bDecreased/borderline.
Table 2. Laboratory data of Fabry patients identified among 117 BSS positive individuals at HD centres
Patient no. Sex Plasma -Gal A
activity
(nmol/h/ml)
Leucocyte -Gal A
activity
(nmol/h/ml)
Urinary
Gb3
GLA
gene
mutation
Exon and
reference
1 M 1.42 2.3 þþ G360S Ex7 (17)
2 M 1.02 14.6  
a A143T Ex3 (7,11)
3 M 0.74 0.8 þ R112H Ex2 (7)
4 M 0.47 1.3 þþ I317T Ex6 (7)
5 F 1.04 22.5 þ Q280K Ex6 (17)
6 F 2.80 27.0   Not detected
7 F 2.50 27.2  
b Not detected
Healthy
controls
MþF
c 2.4–11.3, n¼51
mean 4.79 1.91
32.2–89.0, n¼100
mean 53.8 11.5
 
Classical hemizygote
controls
M 0.17–0.97, n¼23
mean 0.38 0.23
0.3–3.4, n¼31
mean 1.80 0.85
þ, þþ (see ref.6) (17)
Cardiac variant
controls
M 0.25–0.58, n¼3,
mean 0.39 0.17
3.75–7.20, n¼3
mean 5.25 1.77
  N215S Ex5 (7)
Hetero-zygotes
controls
F 0.34–8.25, n¼29
mean 2.06 1.36
6.9–57.4, n¼48
mean 27.7 13.0
 , þ (17)
aAfter kidney transplantation.
bIncrease not significant.
cNon-heterozygocity in females confirmed by GLA gene sequencing.
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activity was relatively high as well but still indicative of
a diagnosis of FD. In the remaining males and females
who had a positive BSS test, measurement of a-Gal A
activity in plasma did not confirm the suspicion of FD.
Summarizing the results from 117 BSS test positive
patients, 4/58 (6.9%) men and 3/59 (5.1%) women
had deficient to borderline a-Gal A activity.
Clinical symptoms
At the time of BSS, clinical symptoms that could
raise suspicion of FD (i.e. angiokeratoma, hypo-
hidrosis, acroparesthesias, corneal and lenticular
opacities and cardiac disease) had not been docu-
mented for the seven newly identified FD patients, and
their clinical condition had not alerted the respec-
tive nephrologists managing their dialysis treatment.
All four males and one female patient in whom
the diagnosis of FD could be confirmed had been
referred and treated under another kidney disease
diagnosis than FD (Table 3).
The illustrative medical histories and clinical
presentations for FD patients 2 and 4 are described
below to demonstrate the diagnostic pitfalls.
Patient 2
This male patient was diagnosed to have diabetes
mellitus type II at age 30 for which he was initiated
on insulin therapy 6 years later. Proliferative reti-
nopathy was treated with laser therapy. Further
symptoms included ischaemic disease of the heart
and lower limbs, arterial hypertension and renal
insufficiency presumed to be caused by diabetic
nephropathy. Renal disease progressed to chronic
renal failure with development of anaemia and
hyperuricaemia. Echocardiography revealed discrete
signs of left ventricular hypertrophy and pulmonary
hypertension. Ejection fraction was 48–50%. At age
45, he started chronic HD treatment, and at that
time he tested positive in the BSS and was identified
as a previously unrecognized FD patient. At age 46,
he underwent a successful kidney transplantation.
Graft function was still normal at the most recent
examination at the Department of Nephrology in
Prague.
The patient’s family history was unremarkable
(no other siblings and/or off-spring) except a mother
who had died at the age of 80 due to pulmonary
embolism.
Table 3. Diagnosis of renal disease and clinical condition in patients with newly recognized Fabry disease as a result of BSS testing.
Patient
no.
Sex Age at
BSS test
(years)
Renal diagnosis Renal biopsy Comments
1 Male 67 Diabetic nephropathy No Psychopathology,
unwilling to share diagnosis
with family members
2 Male 45 Diabetic nephropathy No Kidney transplantation at
age 46
3 Male 64 Tubulointerstitial nephritis no Renal carcinoma, poor
clinical condition, refused
further clinical evaluation
4 Male 26 IgA nephropathy Yes Branched family tree
5 Female 54 Membranoprolipherative
glomerulonephritis
Yes Kidney transplantation at
age 55
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Fig. 1. a-Gal A activity in control and FD plasma samples
compared with values from HD screening patients. Treshold limit
for plasma was set at 3nmol/ml/h (double line). seven samples
(from 117 DBS positive) with decreased or borderline a-Gal A
activities were found(four males and three females). Subsequent
determination of activity in leucocytes and AGAL gene sequencing
confirmed FD in four males and one woman. In two women with
borderline activity, mutation in the GLA gene was not found.
C, control group (n¼51); Het, FD heterozygotes, confirmed by
DNA analysis (n¼29); Hemi, FD hemizygotes, (n¼23); Card,
cardiac variant of FD, (n¼4); F-HD, females from HD screening
(n¼62); M-HD, males from HD screening (n¼55).
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At the age of 16, this male was admitted to the hospital
because of complaints of headache. Some pathological
urinary findings were detected but not further inves-
tigated. At age 26, he was admitted to the district
hospital because of headaches and dyspnoea.
Examinations revealed arterial hypertension, as well
as laboratory signs compatible with advanced renal
insufficiency. Renal biopsy was performed at our
nephrology department, showing mesangial widening
and immunohistological analysis demonstrated slight
IgA deposition. Diffuse glomerular sclerosis was
compatible with histology seen in end-stage kidney
disease. An ultrastructural study was not performed at
that time but, at a later stage, the biopsy specimen
was re-examined by electron microscopy showing
typical signs of FD that had been missed during the
initial examination by light microscopy. The patient
started chronic HD treatment and shortly thereafter
he was found to be positive in the BSS test which led
to the diagnosis of FD. Thorough clinical evaluation
and taking of a detailed medical history revealed clinical
signs and symptoms typical of FD that had been over-
looked previously, e.g. hypertrophic cardiomyopathy,
polyneuropathy, recurrent fever and pain crises.
The patient’s mother who was identified as
a heterozygous carrier during family screening
had been treated for epilepsia, and one brother who
died at age 29 had been receiving chronic HD
treatment for 4 years because of ESRD of uncer-
tain aetiology (the patient was a drug abuser).
The medical histories of the family members and
clinical symptomatology had neither initiated any
diagnostic work-up nor had raised suspicion of FD
until this BSS study.
Genotyping
In all, four males (mean age 50.4 years, range 26–67)
with deficient/decreased a-Gal A activity and in one
(age 54) out of the three women with decreased/
borderline enzyme activity in leucocytes, the mutation
in the GLA gene was found (Table 2, Figure 2).
Of specific interest, the A143T mutation was detected
in male patient 2, i.e. the patient with unusually
high residual leucocyte a-Gal A activity and disease
manifestations apparently limited to the kidney.
Genetic counselling
The diagnostic work-up in the five diagnosed FD
patients included a study of the respective pedigrees
which resulted in the identification of several family
members with unrecognized FD. The family tree
for FD patient 4 (Figure 3) was extremely branched
and three additional FD males and four FD females
could be uncovered. Shortly after the BSS study
was completed and enzyme deficiency had been
confirmed, ERT was started in all five male patients
from this family; three of them were enrolled into a
Fabrazyme (Genzyme Corporation) clinical study
and two were initiated on commercially available
Fabrazyme.
Discussion
All affected men with FD have absent or reduced
activity of a-Gal A which is a prerequisite for using
Fig. 2. Three-dimensional structure of GLA gene and location
of mutations observed in newly diagnosed Fabry patients.
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risk male patient populations. It is expected that such
a screening will identify new FD patients as medical
specialists may be unfamiliar with this rare disorder.
It is not unusual that diagnosis of individuals with
FD symptomatology is delayed for years, or even
decades, due to the phenotypic diversity or failure
to recognize the constellation of early signs and
symptoms. It is illustrative that in one of the patients
(patient 4) enrolled in our study, full blown extra-
renal FD symptomatology remained unrecognized,
and relatively mild FD symptoms did not raise
suspicion in four others (patients 1–3 and 5). Patients
may initially receive a wrong diagnosis that has to be
corrected at a later stage of the disease (e.g. based
on analysis of biopsy specimens) when late, multi-
systemic, life-threatening complications involving the
kidneys, heart and/or central nervous system occur.
In some cases with overt symptoms restricted to one
organ system, autopsy findings may reveal an unex-
pected diagnosis of FD [19]. At present, screening
in high-risk populations allows newly diagnosed Fabry
patients to benefit from the effects of ERT. Indeed,
clearance of Gb3 from storage cells and reduction
of symptoms have been reported [20–22]. Although
fibrotic and sclerotic renal changes cannot be reversed
in advanced patients, ERT may still exert a positive
impact on major non-renal clinical outcomes [23].
As demonstrated by the pedigree study in the fourth
patient’s family, genetic counselling likely identifies
previously unrecognized FD family members in a
relatively early stage of their disease. The outlook
for these patients may dramatically improve if ERT
is initiated as soon as possible after diagnosis. Thus,
early identification of FD patients should be the
primary goal of FD screening initiatives.
In two separate Japanese studies and one Dutch
study, plasma/whole blood samples were used for
quantification of a-Gal A activity in cohorts of males
with chronic HD. Prevalences of FD of 0.45 [8], 1.2 [9]
and 0.22% [24] were calculated. Recently, a new
fully automated fluorescence assay was developed
by Spada and Pagliardini [11] which enables quantifi-
cation of residual a-Gal A activity in whole blood
spots dried on filter paper. In the Italian pilot study,
this BSS method detected four FD hemizygotes in
a cohort of 1765 (0.22%) male ESRD patients [11].
A nationwide BSS study conducted in Austria
enrolled 80.1% of all Austrian chronic HD patients;
85 (3.42%) had a positive BSS result (males 3.50%,
females 3.32%) [12]. Four males, of whom three had
been diagnosed with FD prior to BSS, had a deficient-
Gal A activity in leucocytes and were positively
identified as FD patients by molecular analysis.
In the current study, the same BSS method has
been used for detection of unrecognized Fabry
patients among chronic HD patients in Czech
Republic. Our intention to perform a nationwide
BSS study was largely fulfilled. In fact, our cohort
of 3370 patients (45.1% males, 54.9% females),
represented 83% of the chronic HD patient population
in 2002. This percentage slightly surpasses the propor-
tion of Austrian HD patients (80.1%) screened for FD
[12]. From our cohort of patients who underwent the
BSS test, 117 out of 3370 patients (3.5%) tested
positive (males 3.81%, females 3.19%). Based on
consistently low activity of a-Gal A activity
in plasma and leucocytes, and result of molecular
analysis, overall five new FD patients (4/1521 males,
0.26%; 1/1849 females, 0.05%) could be diagnosed as
a result of our BSS study. The proportion of newly
diagnosed FD patients in our BSS study largely
exceeds the proportion observed in the Austrian BSS
study (1/1516 males, 0.07%; 0/964 females, 0%) [12],
but is comparable with the frequency observed in the
Italian pilot BSS study (4/1765 males, 0.22%) [11]
and the Dutch study using whole blood samples (1/508
males, 0.22%). If the male patient, who was already
known to have FD and, tested positive in the BSS who
is included, the prevalence of FD in Czech HD
patients (both sexes combined) reaches 6 out of 3370
patients (0.18%), which compares with the overall
prevalence in the Austrian cohort (0.16%). The
prevalence of known plus newly diagnosed males
in our study was higher; 5 out of 1521 (0.33%)
HD patients, compared with 0.26%. In our opinion,
the prevalence and other statistical data derived
from our BSS study could be considered as represen-
tative for Czech Republic HD patient population, and
theoretically for other European HD populations,
given the large proportion of patients screened.
The sensitivity of BSS in females is markedly
lower due to the high percentage of false negative
results. Our experience with a large cohort of obligate
heterozygotes confirms that there is a considerable
overlap between the lower range of normal and a-Gal
A activity values found in FD heterozygotes (Table 2).
In approximately one-third of 21 FD females with a
confirmed diagnosis of FD who participated in
a recent BSS study in the Netherlands, a-Gal A
activity was found within the normal range [25].
Therefore, BSS results in females should be interpreted
with caution as a substantial proportion of female
heterozygotes may remain unidentified in spite of
setting broad limits marking the range of ‘suspected’
enzyme activities. Final diagnosis should be established
via molecular analysis.
With regard to percentages of new FD patients
identified using the BSS test, it can be assumed that
only a minor correction could be achieved if the
conditions recommended for handling (sampling,
drying and storage) of the dried blood spot samples
are strictly followed [26]. More favourable BSS testing
results can probably be obtained by optimal selection
of the population tested—for instance by aiming at
patients with renal disease of unknown origin.
However, even such a selection is not free of
imperfections as illustrated by the fact that the
majority of patients diagnosed by BSS had been
labelled with some renal disease other than FD prior
to enrolment in our BSS study (Table 3). In some,
this initial diagnosis was based on renal biopsy analysis
184 M. Merta et al.which suggests that FD-specific biopsy findings
may have been overlooked or were blurred by
histological changes due to concomitant renal disease.
The results of molecular analysis differed between
male and female patients in our study. In all, four men
from the group of seven patients with abnormal or low
borderline a-Gal A activity, the diagnosis could be
confirmed by identification of the GLA mutation.
The failure to detect the genetic defect in two females
with suspicion of FD seems to be in agreement with
the deceiving results of BSS testing in women that were
published recently [25]. In the Austrian cohort, there
were 11 patients (six males, five females) who had a
borderline low leucocyte enzyme activity without a
detectable GLA mutation. It has been suggested that
the molecular analysis method that was used in the
Austrian study (melting point analysis of selected
exons) may have missed some GLA mutations [12].
Molecular analysis is unsuitable as an alternative
method for large-scale screening in at risk populations
as sequencing of the whole GLA gene—a tedious
assay—would be required given the uniqueness of FD
mutations. Moreover, sequencing is not always con-
clusive in heterozygotes, as identification of larger
deletions in heterozygotes with a wild-type allele
may prove to be difficult.
It is of primary importance that the screening
method based on enzyme analysis of dry blood
spots collected on filter paper bypasses the logistic
problems related to transportation of large numbers
of whole blood or frozen plasma samples and,
additionally, BSS is inexpensive. After storage of the
filter papers (up to several weeks) at the recommended
temperature, they can be mailed at ambient tempera-
ture to a specialized centre [10]. From a laboratory
perspective, analysis of blood plasma samples for
screening purposes [9] would be technically easier and
results would be more accurate. However, storage of
large quantities of frozen plasma samples and trans-
portation from distant clinical units to the specialized
laboratory is logistically demanding. BSS is far more
convenient and safe. Final confirmation in patients
with low a-Gal A activity in the dry blood spot test
and plasma assay requires a-Gal activity measurement
in cells, typically in peripheral blood leucocytes
or lymphocytes, in conjunction with DNA-based
mutation analysis [9]. In all patients in our study,
plasma a-Gal A values corresponded well with values
obtained in leucocytes. The high residual activity found
in patient 2 suggests that this patient (A143T hemi-
zygote) has a renal Fabry variant. Two patients
with the same mutation were found among Italian
ESRD patients [11]. High residual a-Gal A activity
has also been reported in a renal variant patient with
the E66Q mutation [9]. These patients lacked the
systemic classical manifestations of FD.
The most important issue that evolves from the
BSS study presented here is the fact that newly
identified patients may be given the opportunity to
benefit from cause-specific treatment. The BSS a-Gal
A activity test and subsequent confirmatory
diagnostic procedures enabled us to diagnose five
new FD patients, four men and one woman. In
addition, many other family members were identified
as Fabry patients by pedigree analysis. Between BSS
study completion (end 2002) and mid 2005, five male
patients have been initiated on ERT and others, who
were offered appropriate palliative care are periodi-
cally monitored to verify if initiation of ERT is
justified and should be proposed to the individual.
The expected clinical benefits for newly recog-
nized patients, as well as for affected family members,
clearly outweigh the challenges related to such a
screening initiative.
Conclusions
Our nationwide study, the largest to date, provides
the rationale for BSS in large cohorts of chronic HD
patients to ensure identification of previously unrec-
ognized Fabry patients. As a result of our screening,
several of the newly diagnosed FD patients and/or
affected family members could be offered effective
treatment in the form of ERT. The convenience and
safety of the BSS method were confirmed. In the
future, FD screening programmes focused on identifi-
cation of undiagnosed FD patients among high-risk
patient populations with kidney disease or other
specific extra-renal manifestations compatible with
FD (e.g. left ventricular hyperthrophy or early
stroke) should be launched. Efforts to increase the
awareness of this disease among the medical commu-
nity should lead to earlier diagnosis of this life-
threatening and disabling genetic disease.
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